These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26469115)

  • 1. Most Recent Evidence Behind Aggregometry and Genotyping Methods as Platelet Function Testing for Tailored Anti-Platelet Treatment Among PCI Patients.
    Gajda SN; Kołtowski Ł; Tomaniak M
    Adv Clin Exp Med; 2015; 24(4):687-93. PubMed ID: 26469115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.
    Cattaneo M
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S16-21. PubMed ID: 24378837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
    Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopidogrel "resistance": where are we now?
    Qureshi Z; Hobson AR
    Cardiovasc Ther; 2013 Feb; 31(1):3-11. PubMed ID: 21884029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
    Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
    Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor agreement between light transmission aggregometry, Verify Now P2Y₁₂ and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: a potential explanation of negative results of recent randomized trials.
    Lemesle G; Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM
    Platelets; 2014; 25(7):499-505. PubMed ID: 24176022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
    Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
    Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High on-clopidogrel treatment platelet reactivity in Thai patients with chronic stable angina scheduled for percutaneous coronary intervention.
    Phankingthongkum R; Panchavinnin P; Chinthammitr Y; Tresukosol D; Chotinaiwattarakul C; Tungsubutra W; Wongpraparut N; Kitrattana B; Leewanun P
    J Med Assoc Thai; 2013 May; 96(5):538-43. PubMed ID: 23745307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
    Sibbing D; Braun S; Jawansky S; Vogt W; Mehilli J; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2008 Jan; 99(1):121-6. PubMed ID: 18217143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study.
    Siller-Matula JM; Francesconi M; Dechant C; Jilma B; Maurer G; Delle-Karth G; Gouya G; Ruzicka K; Podczeck-Schweighofer A; Christ G
    Int J Cardiol; 2013 Sep; 167(5):2018-23. PubMed ID: 22656044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention.
    Gaglia MA; Torguson R; Pakala R; Xue Z; Sardi G; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    J Interv Cardiol; 2011 Dec; 24(6):529-34. PubMed ID: 21919956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
    Sinhal AR; Aylward PE
    Clin Ther; 2013 Aug; 35(8):1064-8. PubMed ID: 23973039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel.
    Hochholzer W; Trenk D; Frundi D; Neumann FJ
    Thromb Res; 2007; 119(3):285-91. PubMed ID: 16603231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of platelet function testing in PCI and CABG patients.
    Janssen PW; ten Berg JM; Hackeng CM
    Blood Rev; 2014 May; 28(3):109-21. PubMed ID: 24745727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.